NIPH Clinical Trials Search

JRCT ID: jRCT2031240039

Registered date:18/04/2024

A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedIdiopathic inflammatory myopathy
Date of first enrollment18/04/2024
Target sample size22
Countries of recruitmentUS,Japan,Argentina,Japan,Australia,Japan,Austria,Japan,Belgium,Japan,Bulgaria,Japan,Canada,Japan,Cyprus,Japan,Denmark,Japan,France,Japan,Georgia,Japan,Germany,Japan,Greece,Japan,Hungary,Japan,Ireland,Japan,Italy,Japan,Republic of Korea,Japan,Lithuania,Japan,Mexico,Japan,Netherlands,Japan,Peru,Japan,Poland,Japan,Portugal,Japan,Serbia,Japan,Spain,Japan,Sweden,Japan,Switzerland,Japan,Taiwan,Japan,Thailand,Japan,Turkey,Japan
Study typeInterventional
Intervention(s)- Experimental: participants receiving efgartigimod PH20 SC on top of background treatment - Placebo Comparator: participants receiving Placebo on top of background treatment


Primary OutcomeTotal improvement score (TIS); measured on a [0,100] scale. Higher scores represent improvement; zero indicates no improvement or worsening
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
Include criteria- Ability to consent in the jurisdiction in which the study is taking place and capable of giving signed informed consent. - A definite or probable clinical diagnosis of idiopathic inflammatory myopathy (IIM) - One of the following medical histories: Diagnosis of dermatomyositis (DM) or juvenile dermatomyositis (JDM), Diagnosis of polymyositis (PM) (including antisynthetase syndrome (ASyS)), Diagnosis of immune-mediated necrotizing myopathy (IMNM) - Diagnosed with active disease as defined by the presence of at least 1 of the following criteria: a. Abnormal levels of at least 1 of the following enzymes: creatine kinase (CK), aldolase, lactate dehydrogenase, aspartate aminotransaminase (AST), alanine aminotransferase (ALT), based on central laboratory results b. Electromyography demonstrating active disease within the past 3 months c. Active dermatomyositis (DM) skin rash d. Muscle biopsy indicative of active idiopathic inflammatory myopathy (IIM) in the past 3 months e. Magnetic resonance imaging within the past 3 months indicative of active inflammation - Muscle weakness - Receiving a permitted background treatment for idiopathic inflammatory myopathy. - Contraceptive use consistent with local regulations, where available, for individuals participating in clinical studies. Women of childbearing potential must have a negative serum pregnancy test during screening and a negative urine pregnancy test at baseline before receiving investigational medicinal product (IMP).
Exclude criteria- A clinically significant active infection at screening - A COVID-19 polymerase chain reaction (PCR)-positive test before enrollment - Any other known autoimmune disease that, in the investigator's opinion, would interfere with an accurate assessment of clinical symptoms of idiopathic inflammatory myopathy (IIM) or put the patient at undue risk - A history of malignancy unless considered cured by adequate treatment, with no evidence of recurrence for >= 3 years before the first administration of the investigational medicinal product (IMP). Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer ; Carcinoma in situ of the cervix; Carcinoma in situ of the breast; Incidental histological finding of prostate cancer - Severe muscle damage - Glucocorticoid-induced myopathy that the investigator considers the primary cause of muscle weakness or permanent weakness linked to a non-idiopathic inflammatory myopathy (IIM) cause - Juvenile myositis (JDM) diagnosed > 5 years from screening or juvenile myositis with extensive calcinosis or severe calcinosis. - Uncontrolled interstitial lung disease or any other uncontrolled idiopathic inflammatory myopathy (IIM) manifestation that, in the opinion of the investigator, would be likely to require treatment with prohibited medication during the study - Other inflammatory and noninflammatory myopathies: inclusion body myositis, overlap myositis), metabolic myopathies, muscle dystrophies or a family history of muscle dystrophy, drug-induced or endocrine induced myositis, and juvenile myositis (other than juvenile dermatomyositis (JDM)) - Clinically significant disease, recent major surgery or intends to have surgery during the study, or has any other condition in the opinion of the investigator that could confound the results of the trial or put the patient at undue risk - Known hypersensitivity reaction to investigational medicinal product (IMP) or 1 of its excipients - Received a live or live-attenuated vaccine less than 4 weeks before screening. - Positive serum test at screening for active viral infection with any of the following conditions: Hepatitis B virus (HBV); Hepatitis C virus (HCV); HIV - Participant has previously participated in an efgartigimod clinical trial and received at least 1 dose of investigational medicinal product (IMP). - Participant is concurrently participating in any other clinical study, including a noninterventional study. - Participant has a current or history (ie, within 12 months of screening) of alcohol, drug, or medication abuse. - Participant is pregnant or lactating or intends to become pregnant during the study. - Participant has severe renal impairment . - Participant is institutionalized by a court or other governmental order or is in a dependent relationship with the sponsor or investigator.

Related Information


Public contact
Name Clinical trial contact
Address 4-1-3 Kyutaro-cho, Chuuou-ku, Osaka-city, Osaka, 541-0056, Japan Osaka Japan 541-0056
Telephone +81-6-4560-2001
Affiliation ICON Clinical Research GK
Scientific contact
Name Coppieters Sabine
Address 4-1-3 Kyuutaromachi, Chuo-ku, Osaka, 541-0056, Japan Osaka Japan 541-0056
Telephone +81-6-4560-2001
Affiliation argenx BV